Literature DB >> 70187

The effect of isoprinosine in subacute sclerosing panencephalitis (SSPE).

L J Streletz, J Cracco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 70187     DOI： 10.1002/ana.410010214

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  8 in total

1.  Unusual features in a case diagnosed as subacute sclerosing panencephalitis (SSPE).

Authors:  K A Flügel; A Barocka; H Woelk
Journal:  J Neurol       Date:  1979-10       Impact factor: 4.849

2.  Long-term survival of a case of subacute sclerosing panencephalitis.

Authors:  C R Barraclough
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-05       Impact factor: 10.154

3.  Cerebrospinal fluid IgG changes in subacute sclerosing panencephalitis in the various stages of the disease and during isoprinosine therapy.

Authors:  M Poloni; B Rocchelli; G Lanzi; F Rosano Burgio; D Besana
Journal:  Ital J Neurol Sci       Date:  1981-05

4.  Extensive form of progressive multifocal leucoencephalopathy associated with laryngeal carcinoma.

Authors:  F Louarn; F Gray; A Gaston; R Gherardi; C Keohane; J D Degos
Journal:  J Neurol       Date:  1987-02       Impact factor: 4.849

Review 5.  Subacute sclerosing panencephalitis.

Authors:  Ravindra Kumar Garg
Journal:  J Neurol       Date:  2008-10-14       Impact factor: 4.849

6.  Progressive rubella panencephalitis: immunovirological studies and results of isoprinosine therapy.

Authors:  J S Wolinsky; P C Dau; E Buimovici-Klein; J Mednick; B O Berg; P B Lang; L Z Cooper
Journal:  Clin Exp Immunol       Date:  1979-03       Impact factor: 4.330

7.  Isoprinosine in classical acute viral hepatitis.

Authors:  K C Lam; H J Lin; C L Lai; S K Lam; Y L Kwan
Journal:  Am J Dig Dis       Date:  1978-10

Review 8.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.